Electronic Supplementary Information:

SmI₂-induced nitrone tandem

β -elimination/alkylation

Emilie Racine^a and Sandrine Py^a*

^a Département de Chimie Moléculaire (SERCO) UMR-5250, ICMG FR-2607, CNRS – Université Joseph Fourier, BP 53, 38041 Grenoble Cedex 09, France.

Sandrine.Py@ujf-grenoble.fr

1- General experimental methods	S2
2- Typical procedures for the preparation of compounds 2 and 4-11 :	S3-S5
3- Characterization of adducts 5-11	S6-S10
4- Copies of ¹ H and ¹³ C NMR spectra for compounds 2 and 4-11	S11-S22
5 - Copie of mass spectrum (ESI) for compound 4	S23

1- General experimental methods

Reactions were performed under Schlenk conditions, with a positive pressure of dry argon in ovendried, or flame-dried glassware equiped with a magnetic stir bar. Standard inert atmosphere techniques were used in handling all air- and moisture-sensitive reagents. Toluene was freshly distilled from sodium. Dry THF was obtained by filtration through activated molecular sieves. H₂O and D_2O (99.97% D) were deoxygenated by refluxing under a current of argon during 30 min. Cyclohexanone and benzaldehyde were distilled over MgSO₄. Cyclopentanone was distilled over 4 Å MS. 3-pentanone was refluxed during 2 hours over CaCl₂, stirred with fresh CaCl₂ during 15 h and distilled. Ethyl glyoxylate in toluene was distilled prior to use then its concentration was measured by ¹H NMR. Cyclohexanecarboxaldehyde, ethyl 3,3,3-trifluoropyruvate and ethyl acrylate were also freshly distilled prior to use. Reactions were monitored by thin layer chromatography (TLC) using commercial aluminum-backed silica gel plates. TLC spots were viewed under ultraviolet light and by heating the plate after treatment with a 3% solution of potassium permanganate in 10% aqueous potassium hydroxyde (w/v). Product purification by gravity column chromatography was performed using Silica Gel 60 (70-230 mesh). Infrared (IR) spectra were recorded on a Fourier Transform spectrometer as neat films. The data are reported in reciprocal centimeters (cm⁻¹) and are assigned as following: br (broad), s (strong), m (medium), w (weak). ¹H NMR and ¹³C NMR spectra were recorded in CDCl₃ (unless otherwise stated). Chemical shifts for ¹H spectra are values from tetramethylsilane in CDCl₃ (δ 0.00). Chemical shifts for ¹³C spectra are values from CDCl₃ (δ 77.16). ¹H NMR spectra are reported as follows: chemical shift (ppm), multiplicity (br: broad; s: singlet; d: doublet; t: triplet; q: quadruplet; m: multiplet), coupling constants (Hz) and integration. Mass spectra (MS) were recorded using the ESI technique. High resolution mass spectra (HRMS) were recorded at the LCOSB, UMR 7613, Université Pierre et Marie Curie, Paris. Elemental analyses were performed at the Service d'Analyse Elementaire du Département de Chimie Moléculaire, Grenoble.

2- Typical procedures:



Preparation of nitrone 2a:

To a solution of carefully deoxygenated nitrone **1a** (50 mg, 0.09 mmol) in THF/H₂O (1:1, 0.6 mL) a 0.1 M solution of SmI₂ (2.0 mL, 0.20 mmol) was added at 0 °C under argon. The temperature was allowed to reach the room temperature in a period of 3.5 h. A saturated aqueous solution of Na₂S₂O₃ (2 mL), a saturated aqueous solution of NaHCO₃ (2 mL) and AcOEt (2 mL) were then added. The phases were separated then the aqueous phase was extracted twice with AcOEt (20 mL). The organic phase was dried over MgSO₄ and concentrated under vacuum to give a residue, which upon column chromatography over silica gel (pentane/AcOEt: 3:1, 1:1 then AcOEt/MeOH: 1:0 then 8:1) yielded **2a** (34 mg, 81%) as a pale yellow oil.

(*3R*,4*R*,5*R*)-3,4,5-tris(benzyloxy)-2-methyl-piperidine 1-oxide (2a): $[\alpha]_{D}^{20} = -54$ (*c* 1.00, CHCl₃); MS (ESI) *m/z* 432 [M+H]⁺; IR ν (neat, cm⁻¹) 3029 (m), 2869 (m), 1612 (m), 1446 (s), 1198 (s), 1071 (s); ¹H NMR (400 MHz, CDCl₃) δ 2.02 (s, 3H), 3.86 (dd, *J* = 1.9 and 4.6 Hz, 1H), 3.94 (br d, *J* = 17 Hz, 1H), 4.03-4.16 (m, 3H), 4.50 (d, *J* = 11.5 Hz, 1H), 4.52-4.66 (m, 4H), 4.73 (d, *J* = 12.0 Hz, 1H), 7.21-7.23 (m, 2H), 7.28-7.38 (m, 13H); ¹³C NMR (75 MHz, CDCl₃) δ 16.0, 58.8, 71.0, 71.9, 72.7, 73.9, 74.1, 76.8, 127.9-128.7, 137.2, 137.5, 137.8, 143.5; Anal. Calcd for C₂₇H₂₉NO₄: C, 75.16; H, 6.78; N, 3.25; Found: C, 74.89; H, 6.80; N, 3.14.



Preparation of nitrone 2b:

To a solution of carefully deoxygenated nitrone **1b** (20 mg, 0.04 mmol) in THF (0.5 mL) a 0.1 M solution of SmI₂ (0.8 mL, 0.08 mmol) was added at -40 °C under argon. The temperature was

allowed to reach -5 °C over a period of 1.5 h. A saturated aqueous solution of Na₂S₂O₃ (2 mL), a saturated aqueous solution of NaHCO₃ (2 mL) and AcOEt (2 mL) were then added. The phases were separated then the aqueous phase was extracted twice with AcOEt (20 mL). The organic phase was dried over MgSO₄ and concentrated under vacuum to give a residue, which upon column chromatography over silica gel (AcOEt/MeOH: 1:0 then 8:1), yielded **2b** (12 mg, 80%) as a pale yellow oil.

(*3R*,4*R*,5*S*)-3,4,5-tris(benzyloxy)-2-methyl-piperidine 1-oxide (2b): $[\alpha]^{20}{}_{D} = -4$ (*c* 0.80, CHCl₃); MS (ESI) *m/z* 432 [M+H]⁺; IR ν (neat, cm⁻¹) 3058 (m), 3033 (m), 2926 (m), 2859 (m), 1606 (m), 1495 (m), 1455 (s), 1094 (s), 1062 (s); ¹H NMR (300 MHz, CDCl₃) δ 2.10 (s, 3H), 3.88-4.13 (m, 5H), 4.56 (d, *J* = 11.4 Hz, 1H), 4.61-4.69 (m, 4H), 4.73 (d, *J* = 11.4 Hz, 1H), 7.26-7.38 (m, 15H); ¹³C NMR (100 MHz, CDCl₃) δ 15.5, 59.9, 72.3, 73.0, 73.4, 73.6, 77.1, 78.2, 128.0-129.0, 131.0, 137.2, 137.3, 137.6, 143.8.



Preparation of deuterated nitrone 4:

Nitrone **1** (50 mg, 0.09 mmol) was co-evaporated three times with toluene (1 mL) at 35 °C and was carefully deoxygenated. To a dry solution of deoxygenated nitrone **1** in THF/D₂O (1:1, 0.6 mL) a 0.1 M solution of SmI₂ (2.0 mL, 0.20 mmol) was added at 0 °C under argon. The temperature was allowed to reach the room temperature in a period of 3.5 h. A saturated aqueous solution of Na₂S₂O₃ (2 mL), a saturated aqueous solution of NaHCO₃ (2 mL) and AcOEt (2 mL) were then added. The phases were separated then the aqueous phase was extracted twice with AcOEt (20 mL). The organic phase was dried over MgSO₄ and concentrated under vacuum to give a residue, which upon column chromatography over silica gel (AcOEt/MeOH: 1:0 then 8:1) yielded **4** (34 mg, 81%) as a beige oil.

(3*R*,4*R*,5*R*)-3,4,5-tris(benzyloxy)-2-monodeuteriomethyl-piperidine 1-oxide (4): $[\alpha]^{20}_{D} = -55$ (*c* 0.74, CHCl₃); MS (ESI) *m*/*z* 455 [M+Na]⁺; IR ν (neat, cm⁻¹) 3033 (m), 2894 (m), 2868 (m), 1606 (m), 1497 (m), 1454 (s), 1194 (m), 1120 (s), 1090 (s); ¹H NMR (400 MHz, CDCl₃) δ 2.00 (s, 2H), 3.86 (dd, *J* = 1.9 and 4.6 Hz, 1H), 3.94 (br d, *J* = 19 Hz, 1H), 4.02-4.16 (m, 3H), 4.50 (d, *J* = 11.5 Hz,

1H), 4.55-4.64 (m, 4H), 4.73 (d, *J* = 12.0 Hz, 1H), 7.21-7.23 (m, 2H), 7.27-7.38 (m, 13H); ¹³C NMR (75 MHz, CDCl₃) δ 15.7 (t), 58.9, 71.1, 72.0, 72.7, 73.9, 74.1, 76.9, 127.9-128.7, 137.3, 137.5, 137.8, 143.0.

General procedure for the preparation of β -functionalized nitrones using Grignard-type conditions (method A):

Nitrone **1** (50 mg, 0.09 mmol) was co-evaporated three times with toluene (1 mL) at 35 °C then was carefully deoxygenated. To the solution of deoxygenated nitrone **1** in dry THF (0.5 mL) a 0.1 M solution of SmI₂ (2.0 mL, 0.20 mmol) was added at -60 °C under argon. After disappearance of the typical blue color, the carbonyl compound (0.20 mmol) was added and the temperature was rised until room temperature during 5 h. A saturated aqueous solution of Na₂S₂O₃ (2 mL), a saturated aqueous solution of NaHCO₃ (2 mL) and AcOEt (2 mL) were added. The phases were separated then the aqueous phase was extracted twice with AcOEt (20 mL). The organic phase was dried over MgSO₄ and concentrated to afford crude oil wich upon column chromatography (pentane/AcOEt : 6:1 to 0:1 then AcOEt/MeOH : 8:1) afforded the pure β -functionalized nitrone (**5-11**) and nitrone **2**.

General procedure for the preparation of β -functionalized nitrones using Barbier-type conditions (method B):

Nitrone **1** (50 mg, 0.09 mmol) was coevaporated three times with toluene (1 mL) at 35 °C then was carefully deoxygenated. To a solution of deoxygenated nitrone **1** and carbonyl compound (0.20 mmol) in dry THF (0.5 mL), a 0.1 M solution of SmI₂ (2.0 mL, 0.20 mmol) was added at -60 °C under argon. The temperature was rised until room temperature during 5 h. A saturated aqueous solution of Na₂S₂O₃ (2 mL), a saturated aqueous solution of NaHCO₃ (2 mL) and AcOEt (2 mL) were added. The phases were separated then the aqueous phase was extracted twice with AcOEt (20 mL). The organic phase was dried over MgSO₄ and concentrated to afford crude oil wich upon column chromatography (pentane/AcOEt : 6:1 to 0:1 then AcOEt/MeOH : 8:1) afforded the pure β -functionalized nitrone (**5-11**) and nitrone **2**.

3- Characterization of adducts 5-11



1-((*3R*,*4R*,*5R*)-*3*,*4*,*5*-tris(benzyloxy)-1-oxy-*3*,*4*,*5*,*6*-tetrahydro-pyridin-2-ylmethyl)-cyclohexanol (5a) was obtained by method A from cyclohexanone (21 μL, 0.20 mmol) and nitrone **1a** (50 mg, 0.09 mmol) as a pale yellow oil (26 mg, 53%) or by method B from cyclohexanone (21 μL, 0.20 mmol) and nitrone **1a** (50 mg, 0.09 mmol) as a pale yellow oil (30 mg, 61%): $[\alpha]^{20}{}_{D} = -87$ (*c* 1.00, CHCl₃); MS (ESI) *m*/*z* 530 [M+H]⁺; IR v (neat, cm⁻¹) 3402 (br), 3254 (br), 3021 (m), 2926 (s), 2849 (s), 1603 (m), 1493 (m), 1456 (s), 1349 (m), 1210 (m), 1063 (s); ¹H NMR (300 MHz, CDCl₃) δ 1.02-1.76 (m, 10H), 2.23 (d, *J* = 13.7 Hz, 1H), 2.88 (d, *J* = 13.7 Hz, 1H), 3.86 (dd, *J* = 1.8 and 4.1 Hz, 1H), 3.92 (dd, *J* = 4.1 and 14.1 Hz, 1H), 4.03-4.18 (m, 3H), 4.34 (d, *J* = 11.7 Hz, 1H), 4.53-4.64 (m, 4H), 4.74 (d, *J* = 12.2 Hz, 1H), 6.26 (s, 1H), 7.10-7.20 (m, 2H), 7.27-7.40 (m, 13H); ¹³C NMR (75 MHz, CDCl₃) δ 22.4, 25.9, 38.1, 39.9, 41.6, 58.4, 71.1, 72.1, 72.7, 72.9, 73.7, 74.2, 76.3, 127.9-128.8, 136.8, 137.5, 137.8, 146.2; HRMS (ESI) Calcd for C₃₃H₄₀N₁O₅: *m*/*z* = 530.29010 [M+H⁺]; Found *m*/*z* = 530.28998.



1-((3R,4R,5S)-3,4,5-tris(benzyloxy)-1-oxy-3,4,5,6-tetrahydro-pyridin-2-ylmethyl)-cyclohexanol

(**5b**) was obtained by method A from cyclohexanone (21 µL, 0.20 mmol) and nitrone **1b** (50 mg, 0.09 mmol) as a pale yellow oil (29 mg, 60%): $[\alpha]^{20}{}_{\rm D} = -22$ (*c* 0.50, CHCl₃); MS (ESI) *m/z* 530 [M+H]⁺; IR v (neat, cm⁻¹) 3242 (br), 3057 (m), 3021 (m), 2922 (s), 2853 (s), 1607 (m), 1493 (m), 1448 (s), 1210 (m), 1071 (s); ¹H NMR (400 MHz, CDCl₃) δ 1.00-1.15 (m, 2H), 1.24-1.38 (m, 3H), 1.46-1.66 (m, 5H), 2.46 (d, *J* = 13.6 Hz, 1H), 2.94 (d, *J* = 13.6 Hz, 1H), 3.82-3.92 (m, 2H), 3.93-4.02 (m, 1H), 4.05-4.15 (m, 2H), 4.45 (d, *J* = 11.6 Hz, 1H), 4.52-4.63 (m, 4H), 4.65-4.69 (m, 2H), 6.25 (s, 1H),

7.25-7.39 (m, 15H); ¹³C NMR (100 MHz, CDCl₃) δ 22.2, 22.3, 25.9, 38.3, 39.7, 41.3, 59.5, 72.0, 72.7, 73.1, 73.2, 74.1, 75.0, 77.2, 127.9-128.8, 136.8, 137.2, 146.5; HRMS (ESI) Calcd for C₃₃H₄₀N₁O₅: *m*/*z* = 530.29010 [M+H⁺]; Found *m*/*z* = 530.29017.



1-((*3R*,4*R*,5*R*)-3,4,5-tris(benzyloxy)-1-oxy-3,4,5,6-tetrahydro-pyridin-2-ylmethyl)-cyclopentanol (6) was obtained by method A from cyclopentanone (18 μL, 0.20 mmol) and nitrone **1a** (50 mg, 0.09 mmol) as a pale yellow oil (30 mg, 63%)or by method B from cyclopentanone (18 μL, 0.20 mmol) and nitrone **1a** (50 mg, 0.09 mmol) as a pale yellow oil (28 mg, 58%): $[\alpha]^{20}_{D} = -77$ (*c* 0.36, CHCl₃); MS (ESI) *m*/*z* 516 [M+H]⁺; IR v (neat, cm⁻¹) 3254 (br), 3062 (m), 3029 (m), 2951 (s), 2869 (s), 1599 (m), 1493 (m), 1448 (s), 1198 (m), 1050 (s); ¹H NMR (400 MHz, CDCl₃) δ 1.13-1.76 (m, 8H), 2.29 (d, *J* = 13.7 Hz, 1H), 3.09 (d, *J* = 13.7 Hz, 1H), 3.86 (dd, *J* = 1.9 and 4.0 Hz, 1H), 3.92 (dd, *J* = 4.5 and 14.6 Hz, 1H), 4.02-4.18 (m, 3H), 4.34 (d, *J* = 11.7 Hz, 1H), 4.53-4.64 (m, 4H), 4.74 (d, *J* = 12.2 Hz, 1H), 6.27 (s, 1H), 7.15-7.17 (m, 2H), 7.30-7.37 (m, 13H); ¹³C NMR (100 MHz, CDCl₃) δ 23.0, 23.6, 39.7, 40.4, 41.1, 58.4, 71.0, 72.1, 72.7, 72.9, 73.7, 76.3, 83.5, 128.0-129.7, 136.8, 137.5, 137.8, 146.4; HRMS (ESI) Calcd for C₃₂H₃₈N₁O₅: *m*/*z* = 516.27445 [M+H⁺]; Found *m*/*z* = 516.27433.



3-((3*R*,4*R*,5*R*)-3,4,5-Tris-benzyloxy-1-oxy-3,4,5,6-tetrahydro-pyridin-2-ylmethyl)-pentan-3-ol (7) was obtained by method A from 3-pentanone (21 µL, 0.20 mmol) and nitrone 1a (50 mg, 0.09 mmol) as a pale yellow oil (15 mg, 31%): $[\alpha]^{20}_{D} = -39$ (*c* 0.70, CHCl₃); MS (ESI) *m/z* 518 [M+H]⁺; IR v (neat, cm⁻¹) 3234 (br), 3066 (m), 3028 (m), 2961 (s), 2935 (s), 2875 (s), 1605 (m), 1452 (s), 1366 (m), 1089 (s); ¹H NMR (400 MHz, CDCl₃) δ 0.75 (t, *J* = 7.4 , 3H), 0.81 (t, *J* = 7.4 , 3H), 1.19-

1.51 (m, 4H), 2.19 (d, *J* = 13.7 Hz, 1H), 2.92 (d, *J* = 13.7 Hz, 1H), 3.86 (dd, *J* = 1.9 and 4.1 Hz, 1H), 3.92 (dd, *J* = 4.4 and 14.4 Hz, 1H), 4.04-4.16 (m, 3H), 4.36 (d, *J* = 11.7 Hz, 1H), 4.52-4.63 (m, 4H),

4.75 (d, J = 12.2 Hz, 1H), 6.27 (s, 1H), 7.15-7.18 (m, 2H), 7.28-7.38 (m, 13H); ¹³C NMR (100 MHz, CDCl₃) δ 8.1, 31.9, 32.3, 39.4, 58.4, 71.1, 72.1, 72.7, 72.9, 73.8, 76.5, 77.4, 127.6-128.9, 136.8, 137.5, 137.8, 146.6.



1-cyclohexyl-2-((*3R*,*4R*,*5R*)-*3*,*4*,*5*-tris-benzyloxy-1-oxy-*3*,*4*,*5*,*6*-tetrahydro-pyridin-2-yl)-ethanol (8) was obtained by method A from cyclohexanecarboxaldehyde (25 μL, 0.20 mmol) and nitrone **1a** (50 mg, 0.09 mmol) as a mixture of diastereoisomers (39 mg, 77%, 70:30, pale yellow oil) or by method B from cyclohexanecarboxaldehyde (25 μL, 0.20 mmol) as a mixture of diastereoisomers (39 mg, 77%, 80:20, pale yellow oil). The major diastereoisomer cristallized in pentane/ether (15 mg, 30%): mp 89-90 °C; $[\alpha]^{20}_{D} = -11$ (*c* 0.40, CHCl₃); MS (ESI) *m/z* 544 [M+H]⁺; IR v (neat, cm⁻¹) 3462 (br), 3063 (w), 3024 (w), 2916 (s), 2846 (s), 1718 (m), 1450 (s), 1254 (m), 1116 (s), 1085 (s), 1025 (m); ¹H NMR (400 MHz, CDCl₃) δ 0.85-1.30 (m, 6H), 1.49-1.80 (m, 5H), 2.35 (dd, *J* = 1.6 and 13.2 Hz, 1H), 2.87 (dd, *J* = 9.6 and 13.0 Hz, 1H), 3.71-3.75 (m, 1H), 3.85 (d, *J* = 5.0 Hz, 1H), 3.92-4.14 (m, 3H), 4.23 (d, *J* = 4.9 Hz, 1H), 4.49 (d, *J* = 11.5 Hz, 1H), 4.52-4.73 (m, 5H), 5.29 (d, *J* = 3.7 Hz, 1H), 7.18-7.23 (m, 2H), 7.27-7.40 (m, 13H); ¹³C NMR (100 MHz, CDCl₃) δ 26.3, 26.4, 26.7, 28.0, 29.0, 35.4, 44.9, 59.1, 70.9, 72.1, 72.7, 74.3, 76.6, 77.6, 128.0-128.8, 137.2, 137.4, 137.7, 147.4.



1-phenyl-2-((*3R*,*4R*,*5R*)-*3*,*4*,*5*-tris-benzyloxy-1-oxy-*3*,*4*,*5*,*6*-tetrahydro-pyridin-2-yl)-ethanol (9) was obtained by method A from benzaldehyde (20 μ L , 0.20 mmol) and nitrone **1a** (50 mg, 0.09 mmol) as a mixture of diastereoisomers (29 mg, 56%, 90:10, pale yellow oil). The major diastereoisomer was purified by column chromatography (18 mg, 36 %): $[\alpha]^{20}_{D} = -101$ (*c* 1.00, CHCl₃); MS (ESI) *m/z* 538 [M+H]⁺; IR v (neat, cm⁻¹) 3274 (br), 3062 (m), 3033 (m), 2922 (m), 2869 (m), 1608 (w), 1493 (m), 1452 (s), 1194 (m), 1084 (s); ¹H NMR (400 MHz, CDCl₃) δ 2.88 (dd, *J* =

6.8 and 13.5 Hz, 1H), 3.05 (dd, J = 2.7 and 13.5 Hz, 1H), 3.65 (d, J = 4.6 Hz, 1H), 3.71 (dd, J = 1.8 and 4.6 Hz, 1H), 3.90-4.02 (m, 2H), 4.13 (dd, J = 6.6 and 14.1 Hz, 1H), 4.24 (d, J = 11.5 Hz, 1H), 4.45 (s, 2H), 4.47-4.61 (m, 3H), 5.08-5.15 (m, 1H), 6.74 (d, J = 3.9 Hz, 1H), 7.13-7.25 (m, 9H), 7.27-7.37 (m, 11H); ¹³C NMR (100 MHz, CDCl₃) δ 39.4, 58.8, 70.8, 72.1, 72.3, 73.5, 74.2, 74.8, 76.7, 125.4-128.8, 137.0, 137.4, 137.6, 144.5, 146.9; HRMS (ESI) Calcd for C₃₄H₃₆N₁O₅: *m/z* = 538.25880 [M+H⁺]; Found *m/z* = 538.25854.



2-hydroxy-3-((*3R*, *4R*, *5R*)-*3*, *4*, *5*-tris-benzyloxy-1-oxy-*3*, *4*, *5*, *6*-tetrahydro-pyridin-2-yl)-propionic acid ethyl ester (10) was obtained by method A from ethyl glyoxylate (68 μ L, 0.2 mmol) and nitrone 1a (50 mg, 0.09 mmol) as a mixture of diastereoisomers (20 mg, 40%, 1:1, pale yellow oil): MS (ESI) *m*/*z* 534 [M+H]⁺; IR v (neat, cm⁻¹) 3250 (br), 3062 (m), 3025 (m), 2926 (m), 2869 (m), 1734 (s), 1595 (m), 1493 (m), 1452 (s), 1366 (m), 1206 (s), 1087 (s); ¹H NMR (400 MHz, CDCl₃) δ 1.24 (t, *J* = 7.1 Hz, 3H), 2.87-3.02 (m, 2H), 3.83-3.88 (m, 1H), 3.96 (dd, *J* = 4.2 and 14.7 Hz, 1H), 4.02-4.05 (m, 1H), 4.07-4.21 (m, 3H), 4.22 (d, *J* = 4.8 Hz, 0.55H), 4.32 (d, *J* = 4.8 Hz, 0.45H), 4.46 (dd, *J* = 4.4 and 8.0 Hz, 0.55H), 4.50-4.74 (m, 6.45H), 7.19-7.25 (m, 2H), 7.28-7.38 (m, 13H); ¹³C NMR (100 MHz, CDCl₃) δ 14.3, 34.6, 34.7, 58.9, 59.0, 61.5, 69.8, 70.7, 70.8, 71.1, 72.1, 72.2, 72.6, 72.8, 73.4, 73.8, 74.2, 74.5, 76.0, 77.1, 77.4, 127.9-128.8, 136.8, 137.1, 137.4, 137.6, 137.7, 143.9, 145.0, 173.4, 173.5.



3,3,3-Trifluoro-2-hydroxy-2-((3R,4R,5R)-3,4,5-tris-benzyloxy-1-oxy-3,4,5,6-tetrahydro-pyridin-2-ylmethyl)-propionic acid ethyl ester (11a,b) were obtained by method A from 3,3,3ethyltrifluoropyruvate (25 µL , 0.2 mmol) and nitrone 1a (50 mg, 0.09 mmol) as a mixture of diastereoisomers (15 mg, 27%, 1:1, pale yellow oil). The diastereoisomers were separated by column chromatography (pentane/AcOEt: 3:1 to 0:1). Diastereoisomer **11a** (7 mg, 14 %, pale yellow oil): $[\alpha]^{20}{}_{D} = -95$ (*c* 0.50, CHCl₃); MS (ESI) *m/z* 624 $[M+Na]^+$; IR v (neat, cm⁻¹) 3341 (br), 3024 (m), 2924 (m), 2869 (m), 1745 (s), 1606 (m), 1454 (s), 1263 (s), 1185 (s), 1072 (s); ¹H NMR (300 MHz, CDCl₃) δ 1.18 (t, *J* = 7.1 Hz, 3H), 2.98 (d, *J* = 13.9 Hz, 1H), 3.32 (d, *J* = 13.9 Hz, 1H), 3.80 (dd, *J* = 1.7 and 4.2 Hz, 1H), 3.88 (dd, *J* = 3.8 and 13.8 Hz, 1H), 3.97-4.21 (m, 4H), 4.38 (d, *J* = 4.3 Hz, 1H), 4.54 (s, 2H), 4.56-4.62 (m, 3H), 4.66 (d, *J* = 12.0 Hz, 1H), 7.21-7.24 (m, 2H), 7.27-7.40 (m, 13H), 8.70 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 0.6 (q), 14.0, 33.3, 58.6, 62.8, 70.9, 72.2, 72.6, 72.8, 74.7, 76.3, 77.3, 127.9-128.9, 136.8, 137.3, 137.5, 144.0, 168.7.

Diastereoisomer **11b** (6 mg, 13 %, pale yellow oil): $[\alpha]^{20}{}_{D} = -48$ (*c* 0.50, CHCl₃); MS (ESI) *m/z* 624 [M+Na]⁺; IR v (neat, cm⁻¹) 3341 (br), 3024 (m), 2924 (m), 2868 (m), 1745 (m), 1454 (s), 1263 (s), 1185 (s), 1072 (s); ¹H NMR (300 MHz, CDCl₃) δ 1.26 (t, *J* = 7.1 Hz, 3H), 3.08 (d, *J* = 14.2 Hz, 1H), 3.26 (d, *J* = 14.0 Hz, 1H), 3.81 (dd, *J* = 2.0 and 4.5 Hz, 1H), 3.89 (dd, *J* = 4.1 and 14.6 Hz, 1H), 3.98-4.04 (m, 1H), 4.06-4.25 (m, 4H), 4.45-4.61 (m, 5H), 4.66 (d, *J* = 12.1 Hz, 1H), 7.17-7.23 (m, 2H), 7.28-7.41 (m, 13H), 8.12 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 0.7 (q), 14.0, 33.4, 58.8, 62.9, 70.6, 72.1, 72.7, 73.1, 74.5, 76.0, 77.4, 127.9-128.9, 136.8, 137.4, 137.6, 143.5, 168.5.



4- Copies of 1H and 13C NMR spectra for compounds 2a,b and 4-11























5 - Copie of mass spectrum (ESI) for compound 4

